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Trachoma, caused by repeated ocular infection with Chlamydia trachomatis (Ct), is targeted for 
elimination as a public health problem. Serological testing for antibodies is promising for surveillance; 
determining useful thresholds will require collection of serological data from settings with different 
prevalence of the indicator trachomatous inflammation—follicular (TF). Dried blood spots were 
collected during trachoma mapping in two districts each of Togo and Democratic Republic of the 
Congo. Anti‑Ct antibodies were detected by multiplex bead assay (MBA) and three different lateral 
flow assays (LFA) and seroprevalence and seroconversion rate (SCR) were determined. By most tests, 
the district with > 5% TF (the elimination threshold) had five–sixfold higher seroprevalence and tenfold 
higher SCR than districts with < 5% TF. The agreement between LFA and MBA was improved using a 
black latex developing reagent. These data show optimization of antibody tests against Ct to better 
differentiate districts above or below trachoma elimination thresholds.
Trachoma, an eye disease caused by repeated ocular infection with the bacterium Chlamydia trachomatis (Ct), 
is the leading infectious cause of blindness and is targeted for elimination as a public health problem. The 
elimination target of less than 5% trachomatous inflammation—follicular (TF) in children aged 1–9 years leaves 
open the possibility of low-level transmission after the cessation of interventions. These interventions—mass 
drug administration (MDA) of antibiotics and campaigns to encourage facial cleanliness and environmental 
improvement—comprise the A, F, and E components of the SAFE strategy (“S” is for surgery to correct morbid-
ity associated with in-turned eyelashes that rub against the eyeball: trichiasis)1. Tools are needed to monitor for 
recrudescence in settings where elimination of trachoma as a public health problem has been validated.
A growing body of evidence demonstrating the utility of serology for post-validation surveillance is being 
 generated2–9. While serology has no diagnostic utility for trachoma at an individual level, the longevity of the 
anti-Ct antibody responses is appropriate for assessing trends in transmission at population level over time. This 
may be particularly apposite for trachoma, for which host immune responses to repeated ocular Ct infections 
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are critical for development of  pathology10–13. One important question is an appropriate threshold of seroposi-
tivity to trigger-decision-making by trachoma programs. Preliminary models from multi-country serological 
data analyses suggest that a mean seroprevalence less than 6.2% and a seroconversion rate (SCR) of below 1.5 
per 100 individuals per year in 1–9-year-olds correspond to TF < 5%6. However, more data are needed to evalu-
ate the relationship between overall seroprevalence, SCR and TF prevalence in settings at various stages of the 
elimination process.
Another important consideration for serosurveillance studies is the choice of test to measure anti-Ct anti-
bodies. Because of the discordance between the longevity of infection and antibody positivity, there is no gold 
standard for antibody tests—i.e., a test that can tell who has been exposed sufficiently to generate an antibody 
response. Antibodies against Pgp3 were first identified by  ELISA14, and subsequently have undergone various 
 revisions15–17. We previously adapted testing for anti-Pgp3 antibodies to a multiplex bead assay (MBA), in order 
to allow evaluation of antibody tests in trachoma-endemic settings within a multiplexed, integrated, serological 
surveillance  platform3. This was later modified to an ELISA with a series of plate control standards to normalize 
absorbance values and thereby standardize testing between  laboratories15. The test was also adapted to a lateral 
flow assay (LFA) to provide a rapid, low-cost, low-technical capacity alternative to ELISAs or  MBA18,19.
As tests are trialed in an increasing variety of epidemiological settings, it is important to use the data and 
user feedback to undertake further test optimization, and ultimately work towards rationalizing the menu of 
options available while consensus emerges on the target product profile. Here, we compare seroconversion rate 
(SCR) and seroprevalence estimates from four evaluation units in two countries undergoing baseline mapping 
for trachoma (Togo and Democratic Republic of the Congo [DRC]) using multiple versions of the LFA and the 
MBA, including an improved version of the LFA that employs black latex as the developing reagent.
Methods
Ethics. Ethical approval for individual studies was given by institutional review boards at the Togo Ministry 
of Health and Social Protection and the Ethics Committee of the Ministry of Public Health of the Democratic 
Republic of the Congo. Written informed consent from parents was obtained for study participants, all of whom 
were aged < 18 years. Tropical Data has ethics approval from the London School of Hygiene & Tropical Medicine 
to support health ministries to conduct trachoma prevalence surveys. CDC staff did not interact with study 
participants or have access to identifying information and were considered to be non-engaged in research. All 
methods were carried out in accordance with relevant guidelines and regulations.
Study sites. In general, an evaluation unit (EU) is a district. For trachoma elimination purposes, WHO 
defines a district as the normal “administrative unit for health care management [which] for purposes of clarifi-
cation consists of a population between 100,000–250,000 persons”20. In Togo, baseline mapping was conducted 
in seven districts in August–September 2017 to determine possible needs for intervention; in 2 of those districts, 
fingerprick blood was collected to create dried blood spots (DBS) and conduct field testing of the Pgp3 lateral 
flow assay. In DRC, DBS were collected in June 2018 as part of baseline mapping in 2 health zones of Tanganyika 
Province. The underlying surveys were conducted in accordance with WHO recommendations for trachoma 
prevalence  surveys21 with the research element built onto that scaffold. In each EU, a two-stage cluster random 
sampling design was used to sample 25 villages (clusters) with probability of selection proportional to popula-
tion size, and 30 households per cluster. In one EU (Nyemba) only 24 clusters were included in the analysis as 
one cluster was inadvertently surveyed twice. All household residents aged 1 year or more were examined for 
clinical signs of trachoma.
TF grading. Graders for all studies underwent training from certified Tropical Data trainers, using inter-
national protocols developed by the Global Trachoma Mapping  Project22. TF was defined as the presence of 
5 or more follicles, each at least 0.5 mm in diameter, in the central part of the upper tarsal conjunctiva of one 
or both  eyes22. Data were entered into standardized forms on Android smartphones by Tropical Data-certi-
fied data recorders. Data recording, cleaning and analysis were done according to published quality assurance 
 mechanisms23.
DBS collection. Fingerprick blood was collected onto filter paper containing 6 circular extensions cali-
brated to each absorb 10 µL of blood (TropBio Pty Ltd., Townsville, Queensland, Australia). In DRC, filter paper 
wheels were dried overnight, placed in sealed plastic bags with desiccant and stored in coolers with vaccine cold 
accumulators for transport from the field to the provincial general reference hospital where the DBS were placed 
in cold storage at − 20 °C. The DBS were transported from the provincial hospital to the Department of Tropical 
Medicine of the University of Kinshasa and put into cold storage and DBS were stored long term at − 20 °C with 
desiccant. DBS were shipped at ambient temperatures to CDC for analysis. In Togo, DBS were dried in the field 
at ambient temperature and then overnight at 2–8 °C. DBS were then placed in sealed plastic bags with desiccant 
and kept refrigerated. At the end of the survey, samples were sent to the INH (National Institute of Hygiene) in 
Lomé and stored at − 20 °C. All DBS specimens were shipped at ambient temperatures to CDC with desiccants 
and moisture indicators for analysis.
MBA. Each DBS extension was eluted overnight at 4 °C in PBS containing 0.5% casein, 0.3% Tween 20, 0.5% 
polyvinyl alcohol, 0.8% polyvinylpyrrolidone, 0.02% sodium azide, and 3 µg/mL E. coli extract (Buffer B). DBS 
eluates were diluted in Buffer B to a final dilution of 1:400. Dilutions were tested on the multiplex bead assay as 
previously  described3. Pgp3 and CT694-coupled beads (1250 per antigen per well) were incubated for 1.5 h with 
50 µL of diluted sample. Wells were washed 3 times with PBST (0.3% Tween 20) and incubated with 50 ng bioti-
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nylated mouse anti-human IgG (Southern BioTech, Birmingham, AL) and 20 ng biotinylated mouse anti-human 
IgG4 (Southern BioTech) for 45 min to detect any Pgp3 and CT694 specific IgG bound to the beads. After 3 
washes with PBST, wells were incubated with 250 ng phycoerythrin-labeled streptavidin (Invitrogen, South San 
Francisco, CA) for 30 min. Wells were washed 3 times with PBST and incubated with 50 µL PBS containing 0.5% 
BSA, 0.05% Tween-20 and 0.02% sodium azide to remove any loosely bound antibodies. After one more wash 
with PBST, wells were suspended in 100 µL PBS and plates were stored overnight at 4 °C. The next day, plates 
were read on a Bio-Plex 200 instrument (Bio-Rad, Hercules, CA) equipped with Bio-Plex manager 6.0 software 
(Bio-Rad). The median fluorescence intensity (MFI) with the background from the blank well (Buffer B alone) 
subtracted out (MFI-bg) was recorded for each antigen for each sample. The cutoff of positivity was established 
as an MFI-bg of 1647 for Pgp3 and 347 for CT694 by using receiver operating characteristic curve analysis on 
a panel of 101 samples from ocular Ct PCR-positive individuals from the United Republic of Tanzania and 74 
pediatric samples from New York, NY USA which tested negative by a chlamydial microimmunofluorescence 
assay.
LFA. Manufacturing. Pgp3 LFAs in cassettes for field testing in Togo were manufactured at CDC as previ-
ously  described18. The production of Pgp3 LFA-dipsticks at CDC for the LFA-gold assay has also been previously 
 described19. Pgp3 LFA-dipsticks for the LFA-latex assay were manufactured at CDC as follows: a nitrocellu-
lose membrane (Sartorius, Bohemia, NY) and an absorbent pad were placed on a backing card with a 1–2 mm 
overlap. Pgp3 protein (0.5  mg/mL) and biotinylated bovine serum albumin (BSA-biotin, 1.0  mg/mL; Arista 
Biologicals, Allentown, PA) were dispensed onto the nitrocellulose membrane at a rate of 0.1 µL/mm using a 
BioDot XYZ 3060 dispenser (BioDot, Irvine, CA) and then dried overnight in a desiccator cabinet with a relative 
humidity of less than 20%. Dried membranes were cut into 4 mm strips using an A-point guillotine cutter (Arista 
Biologicals) and stored at room temperature in a desiccator cabinet with a relative humidity of less than 20%.
Training. All field and laboratory LFAs were read by staff who had achieved a score of κ > 0.80 on a panel of 30 
dried blood spot specimens compared to the trainer.
LFA‑field. Blood was run on the Pgp3 LFA cassette in Togo as previously  described18. Fingerprick blood (20 
µL) was transferred into the sample port of the Pgp3 LFA cassette using a micropipette (Safe-Tec, Ivyland, PA). 
Chase buffer (0.3% Tween 20 in PBS) was added to the buffer port and tests were read as positive, negative or 
invalid 30 min later. Due to time constraints in constructing LFA cassettes, this test was run only on the first 1000 
participants in each district.
LFA‑gold. DBS were tested by the LFA-dipstick assay using a gold detector  reagent19. Each DBS extension 
was eluted in 60 µL of LFA buffer (0.5% BSA, 0.3–1% Tween-20, 0.02% sodium azide in PBS) for 4–24 h in a 
flat-bottom 96-well plate (USA Scientific, Ocala, FL). Streptavidin (SA)-gold conjugate (Arista Biologicals) and 
Pgp3-gold conjugate (Expedeon, San Diego, CA) were added to each well no more than 4 h prior to testing. Pgp3 
LFA-dipsticks were placed into each well for 15–20 min. Then, 40 µL of LFA buffer was added. After 5–10 min, 
LFAs were removed and read as positive, negative or invalid.
LFA‑latex. DBS were tested by the LFA-dipstick assay using a black latex detector reagent. Pgp3-latex (Expe-
deon) and SA-gold (Arista Biologicals) were diluted 1:240 and 1:120, respectively, in PBST (0.3% Tween-20 in 
PBS) to create a conjugate mastermix. Each DBS was eluted in 60 µL of conjugate mastermix in a well of a flat-
bottom 96-well plate, overnight at 4 °C. Pgp3 LFA-dipsticks were added to each well and incubated for 15 min, 
until all the liquid was absorbed. PBST (80 µL) was then added to each well to clear the background caused by 
hemolyzed red blood cells on the nitrocellulose membrane. Each LFA was read as positive, negative or invalid 
once the background was completely cleared, which took about 5 min.
Statistical analysis. TF prevalence estimates were calculated using standard Tropical Data analyses, 
using the mean of the age-standardized cluster-level TF proportions (https:// github. com/ itidat/ tropi cal- data- 
analy sis- public). 95% confidence intervals (CIs) were calculated by taking the 2.5th and 97.5th centiles of all 
ordered results after bootstrapping the cluster means over 10,000 iterations. Overall seroprevalence estimates for 
1–9-year-olds were calculated using age-standardized district-level seroprevalence proportions. Seroconversion 
rates were calculated using R (version 3.6.3), as previously described (https:// github. com/ jessm randa ll/ CDC_ 
Multi count ry_ trach oma_ serop roject)6.
Conference presentation. Portions of the data were presented at the Programme Managers Meeting to 
Accelerate Control and Elimination of Neglected Tropical Diseases in the Western Pacific Region, held virtually 
September 1–4, 2020.
Results
Demographic information and TF data. Togo. In Keran district, a total of 1516 1–9-year-olds were 
enrolled in the study. Of these individuals, 788 (52.0%) were male, and 1511 (99.7%) were examined and had 
DBS collected. In Anie district a total of 1461 1–9-year-olds were enrolled in the study. Of these individuals, 708 
(48.5%) were male, and 1414 (96.8%) were examined and had DBS collected. The number of samples tested by 
each assay in each district is shown in Fig. 1. The age-standardized prevalence of TF in 1–9-year-olds was 0.4% 
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[95% CI 0.1–0.6%] in Keran and 0.3% [95% CI 0.1–0.6%] in Anie (Table 1). Intensity of antibody responses by 
year of age are shown in Fig. 2, and the proportion antibody positive by year of age is shown in Fig. 3.
DRC. In Manono, a total of 1599 1–9-year-olds were enrolled in the study. Of these individuals, 784 (49%) were 
male, 1595 (99.7%) were examined and 1591 (99%) had DBS collected. In Nyemba, a total of 1586 1–9-year-olds 
were enrolled in the study. Of these individuals, 846 (53.3%) were male, 1578 (99.5%) were examined, and 1569 
(98.9%) had DBS collected. The number of samples tested by each assay in each district is shown in Fig. 1. The 
prevalence of 1–9-year-olds with TF was 7.3% [95% CI 4.2–12.0%] in Manono and 1.1% [95% CI 0.5–1.8%] in 
Nyemba (Table 1). Intensity of antibody responses by year of age are shown in Fig. 2, and the proportion anti-
body positive by year of age is shown in Fig. 3.
Figure 1.  Flow chart of sample collection in each evaluation unit. Figure was created using draw.io version 
14.3.1 (https:// app. diagr ams. net/).
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Table 1.  Age-adjusted prevalence of trachomatous inflammation—follicular (TF) and anti-Ct antibodies 
by different immunoassays. EU evaluation unit, CI confidence interval, Pgp3 plasmid gene product 3, Ct 
Chlamydia trachomatis, MBA multiplex bead assay, LFA lateral flow assay, ND not done.
Country EU TF% (95% CI) CT694 MBA% (95% CI) Pgp3 MBA% (95% CI)
Pgp3 LFA cassette% 
(95% CI)
Pgp3 LFA gold% (95% 
CI)
Pgp3 LFA black latex% 
(95% CI)
Togo
Keran 0.4 (0.1–0.6) 2.6 (1.2–6.3) 2.8 (1.3–6.5) 8.1 (4.4–14.9) 4.6 (2.3–8.9) 2.4 (1.0–6.0)
Anie 0.3 (0·1–0·6) 4.5 (2.3–9.0) 4.5 (2.4–8.9) 4.2 (1.9–9.8) 4.0 (2.0–8.2) 4.5 (2.3–9.4)
DRC
Manono 7.3 (4.2–11.6) 26.9 (20.9–34.0) 28.3 (22.2–35.5) ND ND 30.0 (23.7–37.2)
Nyemba 1.1 (0.5–1.8) 6.0 (3.4–10.7) 3.9 (1.9–8.0) ND ND 4.7 (2.5–9.0)
Figure 2.  Intensity of antibody response (determined in the multiplex bead assay [MBA]) by age in each 
participating evaluation unit. Manono health zone, Democratic Republic of the Congo (DRC); Nyemba health 
zone, DRC; Keran district, Togo; Anie district, Togo. In each panel, the y-axis shows median fluorescence 
intensity with background subtracted (MFI-bg), and the x-axis shows age in years. Graphs were created using R 
version 3.6.3 (https:// www.r- proje ct. org/).
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Seroprevalence estimates. Table 1 shows the age-adjusted seroprevalence in 1–9-year-olds by test for-
mat for each EU included. The EU with TF > 5% (Manono) had a seroprevalence of > 25% on each of the assays 
(Table 1). The EUs with TF < 5% had a seroprevalence < 5% on all assays except using the LFA cassette in Keran 
(8.1%, 95% CI 4.4–14.9%) and CT694 MBA in Nyemba (6.0%, 95% CI 3.4–10.7%). Confidence intervals were 
overlapping between Pgp3 MBA and each type of test for each EU.
Seroconversion rate estimates. Table  2 shows the seroconversion rate per 100 children per year for 
each test format in each EU. The EU with TF > 5% (Manono) had seroconversion rates above 10 on all tests. The 
EUs with TF < 5% had seroconversion rates below 2 for Pgp3 MBA and Pgp3 LFA latex but not CT694 MBA 
(Nyemba), Pgp3 LFA cassette (Keran) or Pgp3 LFA gold (Keran) (Table 2).
Figure 3.  Proportion antibody positive by age in each participating evaluation unit. Manono health zone, 
Democratic Republic of the Congo (DRC); Nyemba health zone, DRC; Keran district, Togo; Anie district, Togo. 
MBA multiplex bead assay, LFA lateral flow assay, N.D. not done. Graphs were created using R version 3.6.3 
(https:// www.r- proje ct. org/).
Table 2.  Seroconversion rates (SCR) by different immunoassays. EU evaluation unit, CI confidence interval, 
Pgp3 plasmid gene product 3, CT Chlamydia trachomatis, MBA multiplex bead assay, LFA lateral flow assay, 
ND not done.
Country EU
CT694 MBA (95% 
CI) Pgp3 MBA (95% CI)
Pgp3 LFA cassette 
(95% CI)
Pgp3 LFA gold (95% 
CI)
Pgp3 LFA latex 
(95% CI)
Togo
Keran 0.7 (0.5–1.0) 0.7 (0.5–1.2) 5.8 (3.0–10.2) 2.3 (1.2–3.9) 0.6 (0.4–1.2)
Anie 1.1 (0.8–2.0) 1.0 (0.8–1.7) 1.9 (0.8–3.3) 1.3 (0.7–2.8) 1.1 (0.8–1.7)
DRC
Manono 10.1 (8.1–14.1) 10.4 (8.0–13.8) ND ND 10.8 (8.4–14.6)
Nyemba 6.2 (4.2–8.4) 1.1 (0.8–1.6) ND ND 1.8 (1.1–3.2)
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Discussion
Serology is likely to be an important component of surveillance in settings that have eliminated trachoma as a 
public health problem. It is also likely to prove useful in countries in which some EUs have met the TF elimina-
tion prevalence target, but others have not. Serosurveillance has the advantage of using a sample type (blood or 
blood products) that is often collected for other disease surveillance; trachoma programs could therefore poten-
tially use stored specimens, saving resources. But for serology to be widely adapted for trachoma surveillance, 
we must first demonstrate that serological tests are fit for purpose by evaluating their use in population-based 
surveys in trachoma-endemic and non-endemic areas. Here we show distinct differences in seroprevalence and 
SCR in an EU with a relatively low TF prevalence (Manono, DRC, at 7.3% TF) that falls above the elimination 
threshold compared to three other districts with TF < 5%. These data contribute to the growing body of evidence 
that serological data (expressed as either a seroprevalence or seroconversion rate, and generated by either rapid 
or bead-based tests) reflect population-level TF prevalence, and probably provide meaningful signals about 
transmission intensity of ocular Ct. An empirical comparison of serological data with the parameter likely to be 
of pathological significance—the incidence of ocular Ct infection, determined at population level—would be 
exceedingly difficult to undertake.
Seroprevalence in the three districts with TF < 5% in this study was similar to that observed in pre-validation 
surveys in  Ghana24,  Nepal8, and the United Republic of  Tanzania7. The data from Manono, where TF prevalence 
was 7.3%, were similar to those from 1–5-year-olds in Niger when TF prevalence was 7.5% after 3 rounds of 
antibiotic  MDA25. For the Pgp3 LFA cassette in Keran with TF < 5%, the seroprevalence and SCR were both 
higher than the predicted levels for countries in which trachoma is no longer a public health problem (6.2% 
seroprevalence; SCR 1.56). These early modeling predictions will be improved by the inclusion of serological 
data from countries from sub-Saharan Africa, which carries the largest trachoma  burden26. Existing models are 
over-informed by data from Pacific Island nations, which were early adopters of serological testing as a means 
to understand the local discordance between high TF prevalences in children and low prevalences of trachoma-
tous trichiasis and trachoma-related blindness in  adults27–29. The addition of serology testing to baseline surveys 
in pre-intervention trachoma-endemic populations has been identified as an operational research  priority9. 
The rapid implementation of baseline trachoma mapping within the Global Trachoma Mapping Project from 
2012–201630 now leaves few suspected-endemic areas remaining to be mapped, so the current data are likely to 
be especially valuable for informing appropriate thresholds for the use of trachoma serology.
There were several limitations to the current work. The Togo data are limited by having fewer LFA tests run 
in the field than in the laboratory, which may lead to less accurate estimates of seroprevalence compared with 
other tests. The lack of a gold standard reagent prevents us from definitively establishing the accuracy of different 
anti-Ct antibody tests; we currently rely on agreement between tests in population-based studies and triangulat-
ing those data with clinical and infection data to determine the best tests for use. The lack of infection data in 
these surveys therefore also limits our ability to interpret our data. Seropositivity to Ct antigens may result from 
transient exposure to urogenital strains, but these data revealed clear differences in seropositivity and SCR in 
the single district with TF > 5% compared with those < 5% TF. There is a certain degree of subjectivity in reading 
the LFA, so despite strong population-level agreement amongst the different tests, it is difficult to disentangle 
whether between-test variation is due to test performance or inter-rater disagreement.
In baseline mapping of two districts in Togo, population-level estimates for seroprevalence and SCR were 
essentially equivalent when using the Pgp3 MBA, CT694 MBA, and the Pgp3 black latex LFA. Estimates were 
2–3 times higher using the Pgp3-gold dipstick LFA or the LFA-cassette in Keran. The LFA-cassette had previ-
ously shown poorer sensitivity to detect antibodies in individuals known to be ocular-Ct-positive at the time of 
blood  collection15 and incorporation of data based on use of this test with whole blood resulted in poor model 
fits in latent class  analysis31. We have therefore stopped using this test in the field; it is unlikely to be necessary 
to have point-of-care testing for trachoma surveillance as programmatic decisions are made at the EU, rather 
than individual,  level15. The Pgp3-gold dipstick LFA differed only slightly from the MBA and the prevalence 
estimates generated using it had overlapping 95% CIs with those generated using the black latex LFA (the latter 
having been developed in response to population-level serosurveys in which presumed false positives and poor 
inter-rater agreement were problematic). Additional comparison with the Pgp3 MBA in 2 health zones of DRC 
again show strong agreement between MBA-derived seroprevalence, SCR and Pgp3 black latex-derived data. 
These data, coupled with other as-yet-unpublished data, provide support for using black latex as a developing 
reagent for the Pgp3 LFA. Each test has advantages: MBA can be used for integrated serosurveillance and provides 
robust semi-quantitative data, whereas the LFA does not require advanced instrumentation and can be run in 
essentially any laboratory. Having tests available on multiple platforms will allow national trachoma programs 
flexibility in selecting the best one for their particular need, and we have presented here further improvements 
to the test arsenal for future use in population-level serosurveys.
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